Impact of next-generation sequencing on clinical outcomes in advanced EGFR-mutant lung cancer patients after resistance to osimertinib.
Explore this paper's citation graph
Summary
Next-generation sequencing is helpful to understand mechanisms of mechanism of action of Osimertinib in patients with EGFR-mutant non–small-cell lung cancer with acquired T790M mutation.
- Type
- article
- Published
- 2019-05-20
- Cited by
- 2
- References
- 0
- OpenAlex
- https://openalex.org/W2947332762
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:190870166
Keywords
Osimertinib, T790M, Medicine, Lung cancer, Oncology
References
No references recorded for this paper.
Cited by
Related papers
- Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.
- EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors
- P3.01-037 Understanding Mechanisms of Resistance to Osimertinib by Circulating Tumor DNA Genotyping in Advanced Non-Small-Cell Lung Cancer
- P3.02b-032 Association between EGFR T790M Mutation Copy Numbers in Cell-Free Plasma DNA and Response to Osimertinib in Advanced NSCLC: Topic: EGFR Biomarkers
- MA15.07 Different Responses to Osimertinib in Primary and Acquired EGFR T790M-Mutant NSCLC Patients
- EP12.01-23 Combination of Osimertinib plus Capmatinib in a Patient with EGFR-mutant, T790M positive and MET amplification: A Case Report
- JCSE01.21 Different Responses to Osimertinib in Primary and Acquired EGFR T790M-Mutant NSCLC Patients
- Osimertinib Treatment Was Unsuccessful for Lung Adenocarcinoma with G719S, S768I, and T790M Mutations
- Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib